Dual Wide-Coverage CT: A New Era in European Medical Imaging Begins

ROTTERDAM, Netherlands – September 03, 2026

The landscape of diagnostic medicine in Europe is on the cusp of a significant transformation. United Imaging, a global medical technology firm, has officially received CE Mark certification for its uCT SiriuX and uCT SiriuX Ultrix systems. This regulatory milestone clears the way for the commercial rollout of what the company is calling the world's first dual wide-coverage computed tomography (CT) family, a technology poised to challenge established market norms and unlock new clinical possibilities.

The announcement is more than a product launch; it signals the arrival of a next-generation platform designed from the ground up to address the limitations of current imaging technologies. By integrating a novel architecture with advanced detector and X-ray tube technology, the Shanghai-based manufacturer is making a bold play in a market long dominated by European and American giants.

Deconstructing a "Fundamentally New Architecture"

At the heart of the SiriuX platform is a revolutionary Twin-Ring Gantry, a design that breaks from conventional single-gantry systems. This unique architecture houses two wide 16 cm Ultrix detectors and two powerful liquid-metal-bearing X-ray tubes. This combination is the key to the system's three transformative capabilities: synchronized whole-organ dynamic imaging, ultra-high-resolution imaging across a wide area, and whole-body spectral imaging.

"I've been working with CT technology for more than two decades, and truly new architectures don't come along very often. SiriuX is one of them," said Stefan Ulzheimer, General Manager of CT for United Imaging Healthcare Europe. "It represents a fundamentally new approach to high temporal and spatial resolution, and optimized spectral imaging."

The 16 cm detector coverage is a critical feature, allowing clinicians to capture entire organs like the heart or brain in a single, swift rotation. This eliminates the need for "stitching" together multiple smaller scans, a process that can introduce artifacts if the patient moves. The "dual-wide" aspect suggests an even greater capacity for rapid, comprehensive data acquisition. Coupled with a gantry rotation speed as fast as 0.239 seconds, the system can achieve a temporal resolution of just 63 milliseconds—fast enough to freeze the motion of a beating heart and capture its dynamic function in sharp detail.

Furthermore, the platform's spectral imaging capability uses two X-ray sources at different energy levels simultaneously. This allows the system to differentiate between materials that look similar on a conventional CT scan, such as separating iodine-based contrast agents from calcium deposits in arteries. This provides quantitative data about tissue composition, moving CT from a purely anatomical tool to a functional and physiological one.

Reshaping the Competitive Landscape

The introduction of the uCT SiriuX family into Europe is a calculated strategic move. The European medical imaging market is a fiercely competitive arena, with Siemens Healthineers, GE Healthcare, and Philips holding dominant positions. By launching a "world's first" technology, United Imaging is not just competing—it is aiming to leapfrog existing offerings in the premium CT segment.

This move is backed by substantial investment and a clear global strategy. The company reported investing CNY 1.14 billion in research and development in the first half of 2025 alone and has seen its overseas revenue grow to match that figure in the same period. This aggressive push into innovation and international markets reflects a broader trend of Chinese technology companies moving from producing value-based alternatives to leading with cutting-edge, proprietary technology.

The timing is critical, as competitors are not standing still. GE Healthcare, for instance, also recently secured CE Mark for its own advanced photon-counting CT scanner. This sets the stage for a new battleground where competition is defined not just by price, but by the ability to deliver superior diagnostic information, improve workflow efficiency, and enable new clinical applications. For hospitals and clinics, this heightened competition could lead to greater access to state-of-the-art technology, potentially at more competitive price points.

The Clinical Promise: From Pixels to Patient Outcomes

Beyond the technical specifications and market dynamics, the true measure of the SiriuX platform will be its impact on patient care. The system's advanced capabilities promise tangible benefits across multiple medical specialties, particularly in cardiology and oncology.

For cardiac patients, the ability to perform ultra-high-resolution 4D whole-heart dynamic imaging in a single beat could be game-changing. It offers the potential to non-invasively assess coronary plaque stability, visualize complex valve movements before surgical interventions like TAVR (transcatheter aortic valve replacement), and reduce artifacts from metal stents. A clinical trial is already underway to validate the system's ability to derive novel biomarkers for assessing plaque biomechanics, a key factor in predicting heart attacks.

In oncology, ultra-high-resolution, whole-body spectral imaging offers a powerful tool for cancer detection and management. It can enhance the visibility of small or subtle lesions, provide a more accurate characterization of tumors, and allow for a comprehensive assessment of treatment response across the entire body in a single scan. For patients, this translates into faster examinations, reduced anxiety from needing to hold their breath, and the potential for lower radiation and contrast agent doses due to the system's efficiency.

Navigating the Path to Adoption

While the CE Mark opens the door to the European market, it is the first step on a longer journey to widespread clinical adoption. United Imaging must now navigate the complex and varied landscape of national healthcare systems, each with its own reimbursement policies and procurement processes.

To secure reimbursement and convince hospital administrators, the company will need to build a strong case based on robust clinical evidence. This involves demonstrating not only that the technology is safe and effective, but that it provides tangible value by improving diagnostic accuracy, changing patient management, and ultimately enhancing outcomes in a cost-effective manner. The emphasis of the European Union's Medical Device Regulation (MDR) on continuous post-market surveillance means the collection and analysis of real-world data will be crucial.

Mr. Ulzheimer noted the company's "ongoing dialogue with European clinical partners," indicating that this work is already well underway. Building these relationships will be key to translating technological potential into clinical reality. As the first uCT SiriuX systems are installed in European hospitals, the medical community will be watching closely to see if this fundamentally new architecture delivers on its transformative promise.